GlaxoSmithKline Pharmaceuticals has signed a co-production agreement with Japanese drug maker Daiichi Sankyo Company Limited for anti-hypertensive drug Olmesartan Medoxomil and its combinations.

 GlaxoSmithKline (GSK) Pharma, the Indian arm of global drug major GlaxoSmithKline Plc, has signed a co-promotion agreement with Daiichi Sankyo India Pharma Limited (DSIN), the Indian subsidiary of Japanese pharmaceuticals major Daiichi Sankyo Company Limited, to market an anti-hypertension drug and its combinations products in India.  The drug, Olmesartan Medoxomil and its combination products marketed under the brand name Benitec, is currently available in over 50 countries with an annual sales of $2 billion. Olmesartan is an original research patented product of Daiichii Sankyo.

 Last week, GSK Pharma had signed another collaboration agreement with Japan's Astellas Pharma Inc for exclusive rights to distribute an injectable anti-fungal drug micafungin, sold under the brand name Mycamine, in the Indian market.

The agreement was signed between GlaxoSmithKline India Ltd and Daiichi Sanko India Pharma Ltd (DSIPL), a subsidiary of the Japanese pharmaceutical company. Olmesartan, with annual sales of $2 billion, is sold in more than 50 countries worldwide, the company said in the filing. Daiichi Sankyo India is planning to bring many more research products to India in the future. Daiichi Sankyo also plans to launch joint sales of its Benitec, a drug for high-blood pressure, in India in June with GlaxoSmithKline.